FDA Adverse Event Malfunction Summary report: N

OT VERIO IQ METER

MDR report key: 3193549 · Received June 27, 2013

Report

Report Number
3008382007-2013-18621
Event Type
Malfunction
Date Received
June 27, 2013
Date of Event
June 20, 2013
Report Date
June 27, 2013
Manufacturer
LIFESCAN EUROPE, A DIVISION OF CILAG GMBH INTL
Product Code
NBW
PMA / PMN Number
K110637
Removal / Correction Number
2013-IE-017
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
FR
Reporter Occupation
PATIENT

Narratives

Additional Manufacturer Narrative · 1

LIFESCAN (LFS) HAS REQUESTED RETURN OF THE SUBJECT PRODUCT(S) FOR EVALUATION. IF THE PRODUCT(S) ARE RETURNED, LFS WILL EVALUATE IT/THEM AND INFORM FDA OF PRODUCT(S) THAT DO NOT PASS INSPECTION IN A SUPPLEMENTAL REPORT.

Description of Event or Problem · 1

ON (B)(6) 2013 THE LAY USER/PATIENT IN FRANCE CONTACTED LIFESCAN TO REPORT THE ONE TOUCH VERIO IQ METER WAS GIVING INACCURATELY HIGH READINGS. THE SR. MEDICAL SURVEILLANCE SPECIALIST WAS ABLE TO CLASSIFY THE COMPLAINT BASED ON THE INFORMATION PROVIDED TO CUSTOMER SERVICE. ON (B)(6) 2013 THE PATIENT OBTAINED THE BLOOD GLUCOSE READING OF 122 MG/DL ON THE REPORTED METER AND A LABORATORY RESULT OF 86 MG/DL WITHIN 10 MINUTES. AT THAT TIME THE PATIENT EXPERIENCED NO SYMPTOMS OF HIGH OR LOW BLOOD GLUCOSE LEVELS. THE PATIENT TOOK THE ACTION OF CONSUMING LESS SUGAR IN HER DIET; SHE DID NOT SEEK ANY MEDICAL ATTENTION OR TREATMENT. TROUBLESHOOTING REVEALED THE TEST STRIPS WERE IN GOOD CONDITION AND WITHIN OPENED EXPIRATION DATING AND THE PATIENT¿S TESTING TECHNIQUE WAS CORRECT. THE METER AND TEST STRIPS WERE REPLACED. THE PATIENT DID NOT SUFFER AN ADVERSE EVENT DUE TO THE REPORTED METER. THE PATIENT SUFFERED NO SYMPTOMS AND DENIED SEEKING MEDICAL ATTENTION. HOWEVER, AS THE TEST RESULTS FELL OUTSIDE EXPECTED VALUES FOR METER-TO-LAB ACCURACY TESTING, THIS COMPLAINT IS BEING REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
293813 OT VERIO IQ METER GLUCOSE MONITORING SYS/KIT NBW LIFESCAN EUROPE, A DIVISION OF CILAG GMBH INTL 3398960

Patients

Seq Age Sex Outcome Treatment
1 40 YR